Medicare beneficiaries waiting on drug approvals, and the health plans that process those requests, face a fast-approaching deadline. The public comment period for a proposed CMS rule that would formally require Medicare drug plans to resolve most prior authorization decisions within 72 hours closes next Monday. The proposal, designated CMS-0062-P, also sets a 24-hour clock for urgent cases and layers in new digital interoperability requirements, some with compliance milestones as early as October 1, 2027.
A 72-hour standard that already exists on paper but not always in practice
The 72-hour timeframe is not entirely new. Federal regulation 42 CFR 423.568 already sets a 72-hour outer limit for standard Part D coverage determinations. What CMS-0062-P does is reinforce that ceiling across a broader set of drug prior authorization scenarios and pair it with structured data-exchange requirements that plans have not previously been obligated to meet for prescription drugs.
The real operational pressure, then, falls less on the clock itself and more on the digital infrastructure surrounding it. Plans that already answer standard drug requests within 72 hours will see limited change to their decision timelines. But the proposed rule also extends interoperability API standards, originally finalized for non-drug items and services under CMS-0057-F, into the drug benefit. That extension is where the largest compliance costs are likely to land, because it requires plans to build or adapt electronic connections that transmit prior authorization status, reasons for denial, and supporting clinical data in machine-readable formats.
What CMS-0062-P would change by October 2027
According to the CMS fact sheet for the proposed rule, some payers would need to meet new requirements by October 1, 2027. Those requirements go beyond simple response-time enforcement. They include API-based prior authorization workflows, public reporting of approval and denial metrics, and standardized reason codes that let prescribers see exactly why a request was turned down.
CMS framed the proposal as a way to speed up access to Part D and other covered drugs, increase transparency, and reduce administrative burden. For patients, faster and more transparent decisions could mean fewer gaps in medication therapy and less time spent navigating appeals. For prescribers, structured denial reasons could cut the back-and-forth phone calls and faxes that slow resubmissions and contribute to burnout. For plans, the trade-off is upfront technology investment against what CMS expects will be lower long-term processing costs and fewer complaints.
The proposal would align drug prior authorization with broader CMS efforts to standardize electronic data exchange. Under CMS-0062-P, affected plans would have to implement application programming interfaces that can receive prior authorization requests, return real-time status updates, and share decision details using common data standards. Those interfaces are intended to connect with electronic health records, pharmacy systems, and patient-facing tools, reducing reliance on manual uploads and unstructured documents.
Open questions before the comment window shuts
Several gaps in the public record make the comment period especially consequential. CMS has not published data on how many Part D plans currently fail to meet the existing 72-hour standard or how often beneficiaries experience delays beyond that window. Without that baseline, it is difficult to measure how much the proposed rule would improve real-world performance versus simply codifying what compliant plans already do.
Another unresolved issue is how uniformly plans can implement the new APIs across diverse pharmacy benefit management platforms. Smaller sponsors and regional plans may rely on vendors that are still adapting to the interoperability framework first outlined for drugs in the CMS-0062-P overview. Commenters are likely to focus on whether the proposed 2027 dates give enough time for testing, security hardening, and integration with prescriber workflows.
Stakeholders are also weighing how the 24-hour expedited standard will be applied. The proposal preserves the concept of “urgency,” but operational definitions can vary between plans. Patient advocates may use the comment period to press for clearer criteria or automatic expedited review for certain drug classes, while plans may caution against definitions that could effectively turn most requests into urgent ones and strain clinical review capacity.
Transparency requirements raise their own set of questions. Public reporting of prior authorization metrics could spotlight outlier plans with high denial rates or slow turnaround times, but only if the underlying measures are comparable and risk-adjusted. Plans may ask CMS to refine how it will account for differences in enrollee mix, benefit design, and formulary structure so that raw percentages do not mislead beneficiaries shopping for coverage.
Finally, there is the perennial concern about unintended consequences. If plans respond to tighter timelines and new technology costs by narrowing formularies, shifting drugs to higher tiers, or tightening utilization management in other ways, some beneficiaries could see higher out-of-pocket costs even as decision times fall. CMS has signaled that it expects net benefits from reduced administrative friction, but the agency will need detailed feedback from plans, clinicians, and patient groups to calibrate requirements that are ambitious without being destabilizing.
As the comment window closes, the central tension is clear: CMS wants to move drug prior authorization into a more predictable, electronic, and transparent era, while plans are wary of compressed timelines and complex IT builds. The final rule will determine whether the 72-hour standard becomes a consistently enforced reality for Medicare drug coverage-or remains, for many patients, an expectation that exists mainly on paper.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
